Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.52 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.44 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.44 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.44 |
| ▸ | SORD | Q00796 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24928451 | 1.00 | KDM4E (0.52) | KDM4EGPR119RXFP1KMT2ADPP4 | |
| SCHEMBL30718898 | 1.00 | KDM4E (0.52) | KDM4EGPR119RXFP1KMT2ADPP4 | |
| SCHEMBL26863233 | 0.89 | KDM4E (0.59) | KDM4EGPR119RXFP1SORDTP53 | |
| SCHEMBL13035375 | 0.79 | KDM4E (0.52) | KDM4EGPR119RXFP1TP53GRM1 | |
| SCHEMBL1267664 | 0.79 | KDM4E (0.49) | KDM4EGPR119RXFP1KMT2ADPP4 | |
| SCHEMBL18239409 | 0.79 | KDM4E (0.49) | KDM4EGPR119RXFP1DPP4DPP8 | |
| Hydrochloric Acid SCHEMBL18228248 | 0.78 | KDM4E (0.48) | KDM4EGPR119RXFP1DPP4DPP8 | |
| SCHEMBL13703134 | 0.76 | KCNH2 (0.45) | GPR119KMT2A | |
| SCHEMBL6403047 | 0.76 | PLD1 (0.50) | KDM4EGPR119GRM1 | |
| SCHEMBL8318328 | 0.76 | PLD1 (0.50) | KDM4EGPR119GRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-02-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067632-A1 | WEE1 Degrading Compounds and Uses Thereof | WEE1, WEE2, PPME1 | KDM4E 376/4885GPR119 4217/4885RXFP1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.